Schematic of gastric cancer peritoneal metastases illustrating that YAP1 inhibition alone triggers compensatory activation of TAZ, which interacts with TEAD4 and AP-1 to sustain oncogenic signaling. This adaptive response may limit the effectiveness of YAP1-targeted therapy. In contrast, dual inhibition of YAP1 and TAZ suppresses downstream transcriptional activity and promotes tumor suppression, supporting combined targeting strategies.

📖 Commentary Spotlight
Rahul Kumar highlights:
🧠 Transcriptional plasticity drives resistance
🔗 TEAD–AP-1 cooperation sustains malignancy
💡 Supports co-targeting strategies
🔗 www.pivotscipub.com/chp/3/1/0003...
#CancerHeterogeneity #TherapyResistance

In GCPMs:
• YAP1 inhibition → ↑ TAZ activation
• TAZ forms complexes with TEAD4 and AP-1 (c-JUN/FOSB)
• Drives transcription of oncogenic targets (e.g., SOX9, BIRC5, CTGF, CYR61)
➡️ A key mechanism of therapy resistance via transcriptional plasticity
#TumorPlasticity #TherapyResistance

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss the mechanisms of acquired resistance and the models to better study it. Finally, they promote integration of biomarker-driven strategies and cutting-edge technologies to advance predictive and proactive prevention in cancer therapy.

🥳 Our 3rd most downloaded #REVIEW in 2025:

Acquired resistance in cancer: towards targeted therapeutic strategies

#therapyresistance #cancertherapy @NatResCancer
#NRCtop10of2025

Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions Cell plasticity refers to a dynamic program through which cells reprogram their phenotype, acquiring new histologic and molecular characteristics. Recognized as a hallmark of cancer, cellular plastic...

#Review in #MedComm
Tumor Cell Plasticity in Cancer: Signaling Pathways and Pharmaceutical Interventions doi.org/10.1002/mco2...

#DifferentiationTherapy #EpigeneticReprogramming #SpatiotemporalOmics #TherapyResistance #TumorEvolution #TME

Individual genetic differences render some antibody-based therapies ineffective – BioNews Central Individual genetic differences can cause antibody-based therapies to be ineffective in some people. ...

Individual #GeneticDifferences can cause #AntibodyBasedTherapies to be ineffective in some people. 
#AntibodyTherapies #GeneticVariation #TherapyResistance

Obesity-associated fibroblasts reshape the #TME across #cancers, identify the TS.FIBRO.OBESITY.SIG signature linked to #ECM remodeling, #ImmuneSuppression and #TherapyResistance, and highlight key genes that may guide prognosis and treatment.

#OpenAccess: doi.org/10.1016/j.ge...

Reviewing the structure, regulation, and function of RRM2 and its inhibitors, its critical role in promoting tumor malignancy, #TumorImmunity, #TherapyResistance & the #TumorMicroenvironment, with insights into RRM2-targeted therapies. #medsky

#OpenAccess: doi.org/10.1016/j.ge...

🚨 New Review alert - don't miss this

Strength through diversity: how cancers thrive when clones cooperate

🔓 buff.ly/kQAi97p

#TumourHeterogeneity #TherapyResistance #CancerResistance

🚨 New Review alert - don't miss this

Strength through diversity: how cancers thrive when clones cooperate

🔓 buff.ly/kQAi97p

#TumourHeterogeneity #TherapyResistance #CancerResistance

🚨 New EACR Viewpoint alert

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

🔓 buff.ly/05MSKU1

#RASinhibitors #TherapyResistance #CancerResearch @helloeacr.bsky.social

New antibody therapy reawakens immune system to fight pancreatic cancer – BioNews Central Study reveals how pancreatic cancer tumors evade immunity using a sugar disguise, and how a new antibody therapy restores immunity in mice. ...

Study reveals how #PancreaticCancer #tumors evade #immunity using a sugar disguise, and how a new #AntibodyTherapy restores immunity in mice.
#ImmuneEvasion #TherapyResistance

DNA copy-number changes help melanoma develop resistance to immunotherapy – BioNews Central Scientists have uncovered how melanoma, the deadliest form of skin cancer, evolves to resist immunotherapy and have identified a potential strategy to prevent or reverse that resistance. ...

Scientists have uncovered how #melanoma, the deadliest form of #SkinCancer, evolves to resist #immunotherapy and have identified a potential strategy to prevent or reverse that resistance.
#ImmunotherapyResistance #TherapyResistance

Review article by Alexander M. Jordan et al., #Angiocrine and #pericrine signaling: how endothelial cells and pericytes drive cancer progression and therapy resistance
➡️ https://ow.ly/t2kR50X8pG3
#TherapyResistance #EndothelialCellsandPericytes

This review summarizes AXL’s structure, regulation, and crosstalk with #RTKs, highlighting its role in #TherapyResistance and the translational potential of AXL-targeted treatments. @bostonchildrens.bsky.social #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

Cancer Cells Under Pressure: What Inheritance Reveals About Therapy Resistance UZH researchers have developed a method to live-track cancer cells across generations, uncovering how stress-induced DNA damage leads to heterogeneity and resistance.

What if cancer cells passed stress down like a family secret? Scientists reveal how DNA damage changes generations of tumor cells — and why that matters. #CancerResearch #CellTracking #TherapyResistance

Targeting rapid TKI-induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

➡️ buff.ly/eFq3UeO

#TherapyResistance #CancerTherapy

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

👉 buff.ly/NDTrckS

🥼 @MayaDadiani

#BCSM #TherapyResistance

Our latest webinar series, Unlocking the Full Potential of #PrecisionOncology through Next-Gen Molecular Analysis, starts this Thursday! Join us and explore advanced #diagnostics, #biomarker discovery and strategies to overcome #TherapyResistance. Register here: t.co/GQAibyU0sW

ISCaM 2025 | 12th meeting - Brussels 2-4 July 2025 The 12th edition will be held again at the BEL Congress Centre, in Brussels from July 2nd to 4th, 2025.

SAVE THE DATE: 12th ISCaM meeting - Brussels, 2-4 July 2025. Travel awards available, abstract submission deadline: 30th of April. #spatialMetabolomics #TumourMicroenvironment #CircadiaClock #tumourAcidosis #immunometabolism #cancer #therapyResistance
Info & registration here: iscam2025.org

Out in @naturegenet.bsky.social: Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Amazing work by @sleemmz.bsky.social
👏 Check it out here: rdcu.be/d9kD0 👈 #colorectalcancer #CRC #organoids #therapyresistance #oncofetal #reprogamming Congrats!!

I anticipate exciting things from our Developmental Oncogene Laboratory this year. @baylorhistory.bsky.social #CancerResearch #CellSignaling #AgingResearch #TumorMicroenvironment #TherapyResistance

We have two fully funded #Postdoctoral
positions:
-One dark genome explorer to lead a curiosity-driven project on #lncRNA
in #cancer #therapyresistance
-One experienced researcher interested in working on #drugdevelopment in collaboration with industrial partners
The links to apply below:

Ximena's review is out, congratulation!
Toll-Like Receptor 3 in #Solid #Cancer and #Therapy #Resistance
by Ximena Maria Muresan, Jan Bouchal, Zoran Culig and Karel Souček
👉
#TLR3
#dsRNA
#Cytokines
#therapyresistance

mdpi.com/2072-6694/12/1…